Clinical Trials
Contribute to advancing Metabolic Psychiatry®!
If you are an individual interested in exploring the intersection of metabolic health and psychiatric disorders, on this page, you will find opportunities to participate in or learn about ongoing and upcoming trials aimed at understanding and treating illnesses like ADHD, bipolar disorder, schizophrenia, depression and anxiety, addiction, and eating disorders and obesity utilizing metabolic treatments.
Explore Clinical Trials
-
Anu Ruusunen, PhD
This randomized, controlled pilot study aims to investigate the feasibility of a Modified Ketogenic Diet intervention protocol in psychotic inpatients, and the potential impact of this intervention on psychotic symptoms, depressive and anxiety symptoms, and functioning in patients with psychotic symptoms / psychotic disorder.
Externally-conducted
-
Prof Harry Campbell, Prof Ian Campbell, Dr Nicole Needham
This study will pilot the introduction of a KD for 8 weeks in patients with Bipolar Disorder. The aim is to find out how easy it is to do this, the main challenges, and how to address these.
-
Lilamand Matthieu, MD, PhD
This study aims at examining the feasibility of a KD followed-up for one year in participants with early AD . Change in brain metabolism will be assessed using PET scan after 12 months, comparing KD with control diet. The effects on cognition, quality of life and daily living functioning will be analyzed.
Externally-conducted
-
Russell Serdlow, MD
Researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
Externally-Conducted
-
Sarah Bohlman, MS
The study will include volunteers who have mild cognitive impairment, who will be randomly assigned to receive either a ketogenic low-carbohydrate diet or a low-fat diet for 16-weeks, with follow-up assessment 8 weeks after diet completion. Study measures, clinic visits and phone sessions will occur at baseline and throughout the 24-week study.
Externally-Conducted
-
Jeff Volek, PhD
The goal of this study is to examine whether a well-formulated ketogenic diet (KD) can be implemented into a university counseling treatment program for major depression and to test whether such a program has any benefit on mental and metabolic health.
Externally-Conducted
-
Guido Frank, PhD
This study will investigate the effects of therapeutic ketogenic diet (TKD) on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who have been weight normalized (body mass index of 17.5 or greater) but continue to struggle with eating disorder behaviors including a high drive for thinness and body dissatisfaction.
Externally-Conducted
-
Deanna Kelly, PharmD
A ketogenic diet shows promise for treating schizophrenia and schizoaffective disorder. This study will evaluate the effects of a ketogenic diet on schizophrenia and schizoaffective disorder in an inpatient setting.
Externally-Conducted
-
Carlo Longhitano & Zoltan Sarnyai
Adult community participants with a diagnosis of either bipolar disorder, schizophrenia, or schizoaffective disorder will be randomized to a dietary intervention alongside their treatment as usual. Participants will be assessed for their metabolic health, and social and mental functioning and supported with education and assistance in ensuring adherence to the allocated dietary protocol.
Externally-Conducted
-
Elisa Brietzke, MD, PhD
This is a 12-week, open-label study of the feasibility, safety, and tolerability of adjunctive ketogenic diet for the treatment of individuals with Major Depressive Disorder (MDD). The study will consist of a 2-weeks ketogenic diet induction phase, followed by a 10-week maintenance phase until study endpoint (week-12).
Externally-Conducted
-
Mary Phillips, MD PhD
The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).
Externally-Conducted
-
Min Gao, PhD & Megan Kirk Chang, PhD
Using social media advertising, 100 patients, ages 18-65, who have previously tried at least two different antidepressant medications within the current depressive episode will be recruited. Enrolment, consent, and data collection will be collected online using self-report questionnaires.
Externally-Conducted